Every 10-Q that Compass Therapeutics, Inc. (CMPX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CMPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPX filings page.
Compass Therapeutics is a clinical-stage oncology company advancing four antibody-based programs, led by tovecimig, a DLL4/VEGF-A bispecific for biliary tract cancer. In a Phase 2/3 trial in second-line BTC, tovecimig plus paclitaxel achieved an overall response rate of 18.0% versus 5.3% with paclitaxel alone and a median progression-free survival of 4.7 months versus 2.6 months, with a hazard ratio of 0.44 and p<0.0001.
The company plans to seek FDA feedback on these data in the third quarter of 2026 ahead of a potential BLA submission and will present results at the 2026 ESMO Congress. Additional investigator-sponsored and company-sponsored studies of tovecimig are underway, while Phase 1 trials for CTX-8371 (PD-1 x PD-L1) and CTX-10726 (PD-1 x VEGF-A) continue enrolling, with more data expected in late 2026.
For the quarter ended June 30, 2026, Compass recorded a net loss of $25.154 million (or $0.13 per share), wider than a year earlier, driven by higher research and development and pre-commercialization spending. Cash, cash equivalents and marketable securities totaled $180 million, which management expects will fund operations into 2028, supporting continued clinical development and preparatory commercialization activities.
Compass Therapeutics (CMPX) reported a deeper quarterly loss while strengthening its balance sheet and advancing its lead cancer drug. For the three months ended March 31, 2026, net loss was $18.3 million versus $16.6 million a year earlier, driven mainly by higher general and administrative expenses of $6.9 million, including increased stock-based compensation, while research and development spending was relatively stable at $13.4 million.
Cash, cash equivalents and marketable securities totaled $195 million, and the company believes this will fund operations into 2028. In its oncology pipeline, tovecimig showed statistically significant improvement in overall response rate in second-line biliary tract cancer in a Phase 2/3 study and received FDA Orphan Drug Designation, and the company plans to meet with the FDA ahead of a potential BLA submission.
Compass Therapeutics (CMPX) reported Q3 2025 results, highlighting a stronger balance sheet and continued R&D investment. Cash, cash equivalents and marketable securities were $220 million as of September 30, 2025, and management said this resources level is expected to fund operations into 2028.
Q3 operating expenses were $15.8 million, driven by research and development of $12.8 million (up 49% year over year) and general and administrative of $3.0 million (down 18%). Net loss for Q3 was $14.3 million, or $0.08 per share, and $50.8 million for the nine months.
The company completed an underwritten offering on August 12, 2025, issuing common stock and pre-funded warrants, for net proceeds of $129.3 million. As of October 30, 2025, shares outstanding were 177,862,102.
Pipeline updates included: analyses of overall survival and progression-free survival from the Phase 2/3 BTC study of tovecimig expected in late Q1 2026, and full topline Phase 1 data for CTX-8371 planned for the first half of 2026, with cohort expansions in NSCLC and TNBC planned this quarter.
Compass Therapeutics is a clinical-stage oncology biotech developing antibody-based therapies focused on angiogenesis and immune-oncology pathways. Its lead candidate, tovecimig (DLL4 x VEGF-A), met the study's primary endpoint with a 17.1% overall response rate versus 5.3% for paclitaxel alone (p=0.031), and independent Data Monitoring Committee reviews recommended continuation. The company reports fewer overall survival events than modeled, with pooled OS analyses now expected in Q1 2026.
Financially, Compass recorded a net loss of $19.9 million for the quarter and $36.5 million for the six months, with an accumulated deficit of $401.2 million. Cash, cash equivalents and marketable securities totaled $101 million, which management expects will fund operations into 2027. Research and development expenses rose substantially, driven by increased manufacturing costs for tovecimig and CTX-10726, and the company reported accrued manufacturing obligations including $3.6 million minimum contractual commitments.